Sarah M. Romano's Insider Trades & SAST Disclosures
Sarah M. Romano's most recent trade in Entero Therapeutics Inc. was a trade of 727 Common Stock done at an average price of $0.6 . Disclosure was reported to the exchange on Jan. 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sarah M. Romano.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 06 Jan 2025 | 727 | 17,287 (0%) | 0% | 0.6 | 465 | Common Stock | |
| Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 09 Oct 2024 | 476 | 18,014 (0%) | 0% | 0.4 | 212 | Common Stock | |
| Entero Therapeutics Inc. | Sarah M. Romano | Chief Financial Officer | 02 Jul 2024 | 621 | 18,490 (0%) | 0% | 1.1 | 664 | Common Stock | |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.23 per share. | 01 Apr 2024 | 75 | 19,111 (0%) | 0% | 4.2 | 317 | Common Stock |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.96 per share. | 15 Mar 2024 | 1,120 | 19,186 (0%) | 0% | 5.0 | 5,555 | Common Stock |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 4.20 per share. | 12 Jan 2024 | 98 | 20,306 (0%) | 0% | 4.2 | 412 | Common Stock |
| First Wave BioPharma Inc | Sarah Romano M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 12,614 | 13,404 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 7,000 | 20,404 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.54 per share. | 03 Jul 2023 | 1,977 | 17,476 (0%) | 0% | 1.5 | 3,045 | Common Stock |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.50 per share. | 03 Apr 2023 | 1,975 | 19,453 (0%) | 0% | 2.5 | 4,938 | Common Stock |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| First Wave BioPharma Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 150,000 | 150,000 | - | - | Stock option (right to buy) | |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 05 Jan 2022 | 114 | 22,854 (0%) | 0% | 1.1 | 123 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 07 Dec 2021 | 91 | 22,968 (0%) | 0% | 1.3 | 118 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 83 | 23,059 (0%) | 0% | 2.0 | 164 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.01 per share. | 04 Oct 2021 | 83 | 23,142 (0%) | 0% | 2.0 | 167 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 02 Sep 2021 | 84 | 23,225 (0%) | 0% | 1.8 | 152 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 87 | 23,309 (0%) | 0% | 2.4 | 209 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 180 | 23,396 (0%) | 0% | 3.7 | 666 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 180 | 23,576 (0%) | 0% | 4.2 | 754 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 177 | 23,756 (0%) | 0% | 4.1 | 731 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 180 | 23,933 (0%) | 0% | 4.9 | 889 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 218 | 24,113 (0%) | 0% | 5.5 | 1,190 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 1,282 | 24,331 (0%) | 0% | 6.3 | 8,128 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 25,613 (0%) | 0% | 4.9 | 558 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 97 | 25,819 (0%) | 0% | 3.5 | 340 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 25,916 (0%) | 0% | 3.9 | 380 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 26,014 (0%) | 0% | 3.9 | 382 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 95 | 26,111 (0%) | 0% | 4.1 | 390 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 97 | 26,206 (0%) | 0% | 4.8 | 468 | Common Stock |
| Kiora Pharmaceuticals Inc | Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 94 | 26,303 (0%) | 0% | 5.1 | 480 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges